Corporate
Information

History

History

1972 Itoham Foods Inc, Central Research Institute, established in the Tokyo office.
1987 American Peptide Company established in Silicon Valley, CA, U.S.A.
1990 Itoham Foods Inc, Central Research Institute, relocated to Moriya City, Ibaraki Pref., Japan.
1991 “Hemron,” an iron-rich food supplement that includes heme iron, marketed.
1992 Manufacturing license acquired for “Thrombin,” a drug substance.
c-GMP facility for pharmaceutical peptide production built.
1994 ELCATONIN “ITO,” a drug substance, approved.
1995 “Liver-Hi,” a liver hydrolysate, marketed as a food supplement.
1996 “GLUCAGON FOR INJECTION ‘ITO’,” a glucagon formulation, approved.
1999 “ITORELIN,” a buserelin acetate formulation, approved.
2000 Health Science Division established in Itoham Foods Inc.
2002 c-GMP plant of American Peptide Company built in Vista, CA, U.S.A.
“MINIHEPA INJECTION 500,” a parnaparin sodium formulation, approved.
2003 Ito Life Sciences, Inc. established.
“VETERINARY ITORELIN INJECTION,” a busererin acetate formulation, approved.
“L-Carnitine” and “L-Carnitine Fumarate” marketed.
2004 “RESOLMIN INJECTION 1000,” a dalteparin sodium formulation, approved.
2008 All the shares of Ito Life Sciences, Inc. including American Peptide Company and Ito Life Sciences (Shanghai), transferred to Otsuka Chemical Co., Ltd.
2009 The company name changed to ILS Inc.
2011 “L-Carnitine L-Tartrate” marketed.
2014 “Hemron 2HiWS,” a concentrated and water-soluble heme iron product, marketed.
2015 All the shares of American Peptide Company transferred to Bachem Holding AG.
DESMOPRESSIN NASAL SPLAY 0.01% “ILS,” a desmopressin formulation, approved.
2018 Peptide business transferred to Otsuka Chemical Co., Ltd.
All the shares of ILS Inc. transferred to a subsidiary of Goldman Sachs Japan CO., Ltd. and a subsidiary of ORIX Corporation.
2019 The head office relocated to Kandasuda-cho, Chiyoda-ku, Tokyo for business expansion.
The former head office changed to Moriya Business Operation.

PAGE TOP